Alcon Acquires Majority Interest in Aurion Biotech, Inc. to Advance Innovative Cell Therapy for Corneal Endothelial Disease ...

Aurion is developing AURN001, a clinical-stage allogeneic cell therapy asset, for corneal edema secondary to corneal ...

Learn to spot early warning signs from your eyes that may signal serious health issues and protect your vision before it's ...

Alcon acquired a majority interest in Aurion Biotech, a clinical-stage company developing advanced cell therapies to treat eye diseases. Terms of the deal weren't disclosed.

The global artificial cornea and corneal implant market size was US$ 381.5 million in 2021. The global artificial cornea and corneal implant market is forecast to grow to US$ 701.4 million by 2030 by ...

Frantz EyeCare’s highly-trained specialists strive to provide the most advanced treatment for healthy eyes in all phases of ...

Pakistan: Losartan, a widely used angiotensin II receptor blocker for hypertension, has recently been recognized for its ...

Eye care giant Alcon appears to have gained the upper hand in the ongoing power struggle with Aurion Biotech by securing a ...

Both refractive and corneal astigmatism saw an increase in prevalence in children after the COVID-19 pandemic, with corneal ...

From increased corneal thickness to lower IOP, Australian researchers have delved into the diverse effects of pregnancy on the eye ...